Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$28.7M | -$30.4M | -$21.4M | -$7.83M | -$34.4M | -$47.5M | -$67.1M | -$43.6M | -$49.2M | -$64.5M |
| Net income | -$28.5M | -$30.0M | -$20.7M | -$7.83M | -$34.0M | -$47.3M | -$66.0M | -$40.4M | -$44.6M | -$57.4M |
| EPS (diluted) | -$1.72 | -$2.13 | -$45.80 | -$3.04 | -$4.70 | -$4.21 | -$5.86 | -$3.57 | -$2.17 | -$1.34 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.7M | -$22.4M | -$23.2M | -$5.01M | -$23.4M | -$34.5M | -$26.5M | -$37.6M | -$35.8M | -$56.4M |
| Capital expenditures | $271K | $35.0K | $119K | $475K | $884K | $596K | $120K | $45.0K | $63.0K | $94.0K |
| Free cash flow | -$24.0M | -$22.4M | -$23.4M | -$5.49M | -$24.3M | -$35.1M | -$26.6M | -$37.6M | -$35.9M | -$56.5M |
| Share buybacks | — | — | — | — | — | $228K | $90.0K | $91.0K | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $36.4M | $21.2M | $19.4M | $564K | $169M | $35.7M | $24.1M | $39.6M | $163M | $49.7M |
| Total assets | $43.5M | $44.0M | $23.5M | $1.22M | $203M | $173M | $113M | $79.0M | $181M | $209M |
| Total liabilities | $5.08M | $9.24M | $3.08M | $3.35M | $3.91M | $10.7M | $11.2M | $10.6M | $14.3M | $13.1M |
| Shareholders' equity | $38.4M | $34.7M | $4.78M | -$2.13M | $199M | $162M | $102M | $68.3M | $167M | $196M |
| Retained earnings | -$160M | -$190M | -$210M | -$12.8M | -$46.8M | -$94.0M | -$160M | -$200M | -$245M | -$302M |
| Shares (wtd avg diluted) | 16.6M | 17.7M | 481K | 2.63M | 11.2M | 11.2M | 11.3M | 11.3M | 20.6M | 42.8M |
Every figure is extracted from Protara Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.